Sodium aescinate inhibits microglia activation through NF-κB pathway and exerts neuroprotective effect

Fei Xu, Yiguo Jiang, Xiaoyu Wang, Li Shen, Yan Yan, Dongkai Guo, Cheng WangFrontiers in Pharmacology 2023 · DOI

Abstract

Microglia, the primary immune cells of the central nervous system (CNS), play a dual role in brain health. While essential for homeostasis, their hyper-activation following injury or infection can release neurotoxic mediators, leading to secondary neuronal death. This study investigates the neuroprotective potential of Sodium Aescinate (SA), a compound derived from horse chestnut seeds. Using in vivo traumatic brain injury (TBI) and lipopolysaccharide (LPS) models, alongside in vitro microglial cultures, researchers found that SA significantly inhibits microglial activation. Molecular docking and biochemical assays revealed that SA acts by suppressing the NF-κB signaling pathway, physically binding to core proteins like p65. These findings suggest SA is a promising therapeutic agent for mitigating neuroinflammation and protecting neurons.

Introduction: The Double-Edged Sword of Microglia

In the healthy brain, microglia act as vigilant sentinels. However, traumatic brain injury (TBI) or systemic infections can trigger a dysfunctional state. These "overactive" microglia secrete a cocktail of pro-inflammatory cytokines (such as TNF-α and IL-6) and reactive oxygen species (ROS), which exacerbate tissue damage. Sodium Aescinate (SA) has long been noted for its neuroprotective effects, but its specific impact on microglial behavior remained poorly understood until now.

Methods and Experimental Design

The study employed a multi-faceted approach to map SA's effects:

  • Animal Models: C57BL/6 mice were subjected to a weight-drop TBI model and LPS-induced systemic neuroinflammation.
  • Cellular Models: BV2 and primary mouse microglia were used for in vitro mechanistic studies.
  • Molecular Docking: Computational simulations using structures from the Protein Data Bank (PDB) assessed the binding affinity of SA to NF-κB pathway components (IκK, IκB, and p65).
  • Biochemical Analysis: Western blotting, qRT-PCR, and ELISA were used to quantify inflammatory markers and cytokine secretion.

Results: Suppressing the Inflammatory Cascade

The researchers observed a clear dose-dependent reduction in inflammatory markers when microglia were treated with SA.

Figure 6: Western blot analysis showing that SA dose-dependently inhibits the expression of iNOS and COX-2 in LPS-stimulated microglia.

Key findings include:

  • Cytokine and Mediator Inhibition: SA significantly lowered the levels of IL-6, TNF-α, and Nitric Oxide (NO).
  • NF-κB Pathway Blockade: SA prevented the phosphorylation of IκK and IκB, effectively stopping the p65 protein from entering the nucleus to activate inflammatory genes.
  • High Binding Affinity: Molecular docking showed SA binds strongly to p65 (binding energy of -8.2 kcal/mol), suggesting a direct inhibitory interaction.
Figure 5: ELISA results demonstrating that SA treatment significantly reduces the production of the pro-inflammatory cytokine IL-6 in LPS-challenged microglia.

Neuroprotection and Clinical Implications

A critical "conditioned medium" experiment demonstrated that neurons treated with the secretome of SA-pretreated microglia survived significantly better than those exposed to untreated, activated microglial medium. In TBI models, SA reduced neuronal apoptosis (marked by lower Caspase-3 levels) and the overall count of activated microglia.

Conclusion

This research identifies the NF-κB pathway as a central target for Sodium Aescinate's anti-inflammatory action. By physically interacting with signaling proteins, SA acts as a molecular brake on microglial activation, offering a potent strategy for neuroprotection. Future studies should explore the cross-talk between NF-κB and other pathways like Nrf2-ARE to fully map SA's therapeutic landscape.

Summary updated

Abstract

<b>Background:</b> Microglia are resident immune cells of the central nervous system that sense environmental changes and maintain central nervous system homeostasis. Dysfunctional microglia produce toxic mediators that lead to neuronal death. Recent studies suggest that Sodium Aescinate has a neuroprotective effect. However, it is unclear whether Sodium Aescinate exerts neuroprotective effects by inhibiting activation of microglia. <b>Method:</b> Traumatic brain injury and lipopolysaccharide neuroinflammation model were used to evaluate the microglia activation <i>in vivo</i>. BV2 and primary microglia cells were used to assess the microglia activation <i>in vitro</i>. Molecular docking technique was used to predict the binding energy of Sodium Aescinate to NF-κB signaling pathway proteins. <b>Result:</b> Sodium Aescinate inhibited microglial activation <i>in-vivo</i> and <i>in-vitro</i>. Sodium Aescinate inhibited the activation of microglia in Traumatic brain injury and lipopolysaccharide mouse models. Sodium Aescinate also inhibited the expression of inflammatory proteins in BV2 and primary microglia cells. Western blot experiment showed that SA inhibited the activation of NF-κB pathway in BV2 and primary microglia cells. Molecular docking results also showed that Sodium Aescinate had a better affinity with the core protein of the NF-κB pathway. Western blot identified that SA inhibited activation of NF-κB pathway. In Traumatic brain injury model and conditioned medium experiment, Sodium Aescinate pretreatment inhibited inflammation and protected neuron. <b>Conclusion:</b> Our study confirmed that the protection effects of Sodium Aescinate on neurons by inhibiting microglia activation through NF-κB pathway.
BibTeX
@inproceedings{xu2023sodium,
  author = {Fei Xu and Yiguo Jiang and Xiaoyu Wang and Li Shen and Yan Yan and Dongkai Guo and Cheng Wang},
  title = {{Sodium aescinate inhibits microglia activation through NF-κB pathway and exerts neuroprotective effect}},
  booktitle = {Frontiers in Pharmacology},
  year = {2023},
  doi = {10.3389/fphar.2023.1086429},
}
Figure